Rocket (RCKT) Q2 Loss Narrows 16%
Rocket Pharmaceuticals (NASDAQ:RCKT), a biotechnology company focused on gene therapies for rare and serious diseases, reported its second quarter 2025 results on August 7, 2025. The most significant news was the clinical hold placed on its lead Danon disease gene therapy program following a patient fatality in May 2025, which has prompted a strategic realignment and a major workforce reduction. The company reported a net loss per share of $0.62 (GAAP), but still reflecting deep ongoing R&D investment and the challenges of operating as a pre-commercial biotech. There was no revenue for the period, consistent with expectations, as the company has not yet launched commercial products. Overall, the quarter demonstrated tightened cost controls but heightened operational risks, with significant clinical and strategic changes shaping the outlook for the rest of fiscal 2025.
Source: Analyst estimates for the quarter provided by FactSet.
Rocket Pharmaceuticals develops gene therapies aimed at treating rare and life-threatening diseases, with a focus on conditions where no effective treatments exist. It uses adeno-associated virus (AAV) and lentiviral vector-based platforms to deliver genetic material to address inherited cardiac and blood disorders. The company's lead programs target Danon disease, a severe genetic heart disorder, as well as other conditions like arrhythmogenic cardiomyopathy and leukocyte adhesion deficiency.
Source Fool.com
